Lipocine Inc (NASDAQ:LPCN) currently has a daily average trading volume of 32.16K but it saw 2195488 shares traded in last market. With a market cap of 34.10M USD, the company’s current market price of $6.41 came falling about -1.54 while comparing to the previous closing price of $6.51. In past 52 weeks, the stock remained buoying in the range of price level as high as $6.70 and as low as $2.31.
Taking a look at 20-day trading activity of Lipocine Inc (LPCN) gives us an average price of $4.94, while its current price level is -4.33% below from 52-week high level whereas it is 177.48% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $4.32 while that of 200 days or SMA-200 reads an average of $3.68. A closer look into the stock’s movement over the week reveals that its volatility is standing at 14.62% during that period while stretching the period over a month that decreases to 11.77%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 74.50 which implies that the stock is in overbought territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Cantor Fitzgerald which initiated the stock as “Overweight” in its note to investors issued on June 24, 2021, recommending a price target of $3 for it. Ladenburg Thalmann upgraded its recommendation for the stock as a “Buy” from “Neutral” on December 10, 2020 while assigning a price target of $3. H.C. Wainwright issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $10 and $3.
Over the week, LPCN’s stock price is moving 39.05% up while it is 61.87% when we observe its performance for the past one month. Year-to-date it is 129.75% up and over the past year, the stock is showing an upside performance of 20.47%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of -$0.42 beat the consensus estimate of -$0.47 for the same. For LPCN, analysts are forecasting an EPS-growth rate of 52.50% for current year and estimate for EPS growth in next year is 61.70%. In next quarter, company is expected to be making quarterly sales of $400k as analysts are expecting the sales for current fiscal year at $2.03 million and seeing the company making $16.25 million in sales next year.
Currently, Lipocine Inc’s total number of outstanding shares is 5.32M with 3.03% of that held by the insiders while 9.17% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -80.28% and return on equity (ROE) at -58.40%. Stock’s beta reads 1.04. Stock has a price to book (P/B) ratio of 1.67 while price to sale or P/S ratio amounts to 310.01. Its return on asset (ROA) is -54.02% on average.
